| Filed On | Filing |
|---|---|
| 16 Oct 2025 |
8-K/A: Financial Statements and Exhibits
On July 31, 2025, Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") completed the acquisition ("Acquisition") of Sage Therapeutics, Inc. ("Sage"). The following unaudited pro forma condensed combined statements of operations (... |
| 10 Aug 2023 |
8-K/A: Results of Operations and Financial Condition
–$31.0 million and $56.8 million of net product sales in the second quarter and first six months of 2023, respectively |
| 10 Feb 2022 |
8-K/A: Financial Statements and Exhibits
On November 24, 2021, Supernus Pharmaceuticals, Inc. (Company) completed the acquisition (Acquisition) of Adamas Pharmaceuticals, Inc. (Adamas). The following unaudited pro forma condensed combined statements of operations (pro forma sta... |
| 24 Aug 2020 |
8-K/A: Financial Statements and Exhibits
The following unaudited pro forma condensed combined statements of operations (pro forma statements of operations) give effect to the acquisition of USWM Enterprises, LLC (USWM) by Supernus Pharmaceutical, Inc. (Supernus or the Company),... |
| 09 Nov 2017 |
8-K/A: Submission of Matters to a Vote of Security Holders
(d) As reported in the Original Form 8-K, the advisory, non-binding proposal regarding the frequency of advisory votes on the compensation of the Company’s named executive officers, voted on at the 2017 Annual Meeting, received the follo... |
| 11 Mar 2015 |
8-K/A: Results of Operations and Financial Condition
On March 10, 2015, the Company furnished the Original Form 8-K and included as an exhibit thereto a Press Release announcing its financial results for the quarter and year ended December 31, 2014 and related information (the “Press Relea... |
Loading...
